MAOB and Parkinson disease: The efficacy and safety of the MAOB inhibitor rasagiline have been demonstrated in several randomized controlled trials, both as monotherapy in early PD (Parkinson Study Group 2002, 2004; Olanow et al. 2009) and as adjunct to levodopa in advanced PD (Parkinson Study Group 2005; Rascol et al. 2005).